Ep210: Cameron Turtle on Long-Lasting Antibodies for Immune Disorders

What It Covers

Cameron Turtle, CEO of Spire Therapeutics, explains how the company engineers antibodies with threefold longer half-lives targeting alpha-4-beta-7, TL1A, and IL-23 p19 for inflammatory bowel disease. Spire's platform trial tests six active agents simultaneously, including novel combinations, aiming to push clinical remission rates from roughly 25% toward 50% or beyond.

Key Questions Answered

• •Half-life extension via FcRn binding: The YTE modification (three amino acid substitutions) increases antibody binding to the neonatal Fc receptor at low pH, recycling antibodies back into the bloodstream instead of degrading them. This produces roughly a threefold half-life improvement, enabling dosing intervals to extend from every two weeks to quarterly or twice-yearly injections without altering safety, efficacy, or immunogenicity profiles across dozens of clinical programs.
• •Combination therapy ceiling-breaking: J&J's VEGA trial demonstrated that combining two IBD biologics, each achieving roughly 25% clinical remission individually, produced 47% remission together. Spire applies this logic by co-formulating long-acting antibodies against mechanistically distinct targets — alpha-4-beta-7 on circulating immune cells and soluble TL1A or IL-23 in inflamed tissue — to pursue additive efficacy without the dosing-regimen complexity of mixing separate products.
• •Platform trial efficiency for combination development: Spire's Skyline study tests six active arms in a single platform trial in ulcerative colitis, sharing one placebo arm across all comparisons. This design requires nearly half the patient numbers compared to running three separate combination trials, each needing its own placebo and monotherapy arms. Developers pursuing combination approvals should consider platform designs to compress timelines and reduce capital requirements substantially.
• •Target safety profile is prerequisite for half-life extension: Extending antibody half-life amplifies both efficacy and any adverse events, since the drug clears more slowly if problems emerge. Spire deliberately selects targets with thousands to tens of thousands of existing patient exposures confirming tolerability. Biotech teams engineering extended half-life biologics should prioritize targets with well-established safety records before applying YTE or LS modifications to avoid compounding unknown risks.
• •Fast-follower thesis reduces early-stage capital risk: Spire's probability-of-success calculus differs from novel-target programs because the biology is already validated by approved drugs generating billions in annual revenue. The downside scenario — a more convenient version of a drug doing over $6.5 billion yearly — remains commercially viable. This reframes investor risk: rather than single-digit phase-one-to-approval odds, developers can argue for substantially higher success probabilities when targeting well-characterized mechanisms with improved formulations.
• •Staggered catalyst cadence sustains investor engagement: Spire structured its development program to generate multiple data readouts across a 12-month window — monotherapy results, six combination arms from Skyline, TL1A data in rheumatic diseases, and a TL1A plus IL-17 combination in hidradenitis suppurativa. Biotech companies with broad pipelines should deliberately sequence trial timelines to avoid multi-year catalyst gaps, which force investors to redeploy capital elsewhere and complicate follow-on financing at critical development stages.